Ciprofloxacin
ciprofloxacin 0.3% · ophthalmic solution
Antibiotic
Approved uses
Bacterial corneal ulcer
Two drops every 15 minutes for the first six hours, then two drops every 30 minutes for the remainder of the first day; two drops hourly on the second day; two drops every four hours on the third through the fourteenth day; treatment may be continued after 14 days if corneal re-epithelialization has not occurred
Cures as often as fortified tobramycin-cefazolin, with significantly less discomfort.
Bacterial conjunctivitis
1 or 2 drops in the conjunctival sac q2h while awake x 2 days, then 1 or 2 drops q4h while awake x 5 days.
Eradicated bacteria in 90% of children by day 7, on par with tobramycin.
Contraindications
- A history of hypersensitivity to ciprofloxacin or any other component of the medication
- A history of hypersensitivity to other quinolones may also contraindicate use
Ophthalmic solution, 2.5 mL, 5 mL, 10 mL bottles, 0.3% (3 mg ciprofloxacin base per mL)
Fluoroquinolone; bactericidal through interference with DNA gyrase, the enzyme needed for synthesis of bacterial DNA, with additional inhibition of topoisomerase IV, the primary quinolone target in susceptible Staphylococcus aureus. Broad gram-negative and gram-positive ocular coverage including Pseudomonas aeruginosa, with peak plasma concentrations under 5 ng/mL on the labeled conjunctivitis schedule.
Warnings & Precautions
- White corneal precipitate: In corneal ulcer studies a white crystalline precipitate formed in the superficial portion of the corneal defect in 35 of 210 patients (16.6%), with onset 24 hours to 7 days after starting therapy; it did not preclude continued use and did not adversely affect the clinical course of the ulcer or the visual outcome.
- Precipitate and re-epithelialization: A prospective, multicenter, observational cohort of 624 patients with presumed bacterial keratitis treated with ciprofloxacin 0.3% solution or ointment found a white corneal precipitate in 15.2%, no significant effect on time until therapeutic improvement (P =.09), and a 55% slowing of reepithelialization (95% confidence limits 32%, 70%); risk was 3.7 times higher at age 70 and older than under 40 (95% confidence limits 2.6, 5.0).
- Not for injection into the eye: The solution is for topical use.
- Hypersensitivity (anaphylactic) reactions: Serious and occasionally fatal reactions, some after the first dose, have been reported in patients on systemic quinolone therapy; some were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria and itching, and only a few patients had a history of hypersensitivity reactions. Serious anaphylactic reactions require immediate emergency treatment with epinephrine and other resuscitation measures.
- Nonsusceptible organism overgrowth: Prolonged use may result in overgrowth of nonsusceptible organisms including fungi; start appropriate therapy if superinfection occurs. Whenever clinical judgment dictates, examine the patient with magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
- Hypersensitivity rash: Discontinue at the first appearance of a skin rash or any other sign of hypersensitivity reaction.
- Contact lens wear: Remove lenses before instillation.
- Contamination: Do not touch dropper tip to any surface, as this may contaminate the solution.
- Drug interactions: Specific drug interaction studies have not been conducted with ophthalmic ciprofloxacin; systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, enhance the effects of warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
Common Side Effects
The most frequently reported drug related adverse reaction is local burning or discomfort. In corneal ulcer studies with frequent administration, white crystalline precipitates were seen in approximately 17% of patients. Other reactions occurring in less than 10% of patients include lid margin crusting, crystals or scales, foreign body sensation, itching, conjunctival hyperemia, and a bad taste following instillation. Additional events occurring in less than 1% of patients include corneal staining, keratopathy or keratitis, allergic reactions, lid edema, tearing, photophobia, corneal infiltrates, nausea, and decreased vision.
Pregnancy: Category C. Reproduction studies in rats and mice at up to six times the usual daily human oral dose showed no impaired fertility and no fetal harm; oral dosing in rabbits at 30 and 100 mg/kg caused gastrointestinal disturbance, maternal weight loss and increased abortion without teratogenicity, and intravenous dosing up to 20 mg/kg produced no maternal toxicity, embryotoxicity or teratogenicity. No adequate and well controlled studies in pregnant women; use only if the potential benefit justifies the potential fetal risk.
Lactation: Excretion of topically applied drug in human milk is unknown; oral dosing is excreted in the milk of lactating rats and has been reported in human breast milk after a single 500 mg dose; use caution in a nursing mother.
Safety and effectiveness established in all ages, including neonates.